Lin SH - Search Results

1

Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum?

Ortiz A, Lin SH. Ortiz A, et al. Among authors: lin sh. Recent Results Cancer Res. 2012;192:225-33. doi: 10.1007/978-3-642-21892-7_11. Recent Results Cancer Res. 2012. PMID: 22307378 Review.

2

Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features.

Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Tu SM, et al. Among authors: lin sh. Cancer. 2002 May 15;94(10):2610-7. doi: 10.1002/cncr.10546. Cancer. 2002. PMID: 12173328 Free article.

3

Clinical aspects of bone metastases in prostate cancer.

Tu SM, Lin SH. Tu SM, et al. Among authors: lin sh. Cancer Treat Res. 2004;118:23-46. doi: 10.1007/978-1-4419-9129-4_2. Cancer Treat Res. 2004. PMID: 15043187 Review. No abstract available.

4

Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow.

Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Vakar-Lopez F, et al. Among authors: lin sh. J Pathol. 2004 Jun;203(2):688-95. doi: 10.1002/path.1568. J Pathol. 2004. PMID: 15141384

5

Osteoblasts in prostate cancer metastasis to bone.

Logothetis CJ, Lin SH. Logothetis CJ, et al. Among authors: lin sh. Nat Rev Cancer. 2005 Jan;5(1):21-8. doi: 10.1038/nrc1528. Nat Rev Cancer. 2005. PMID: 15630412 Review.

6

Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.

Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Tannir N, et al. Among authors: lin sh, lin p. Cancer. 2006 Aug 1;107(3):497-505. doi: 10.1002/cncr.22038. Cancer. 2006. PMID: 16795067 Free article. Clinical Trial.

7

The central role of osteoblasts in the metastasis of prostate cancer.

Choueiri MB, Tu SM, Yu-Lee LY, Lin SH. Choueiri MB, et al. Among authors: lin sh. Cancer Metastasis Rev. 2006 Dec;25(4):601-9. doi: 10.1007/s10555-006-9034-y. Cancer Metastasis Rev. 2006. PMID: 17160554 Review.

8

Biology and clinical management of prostate cancer bone metastasis.

Ye XC, Choueiri M, Tu SM, Lin SH. Ye XC, et al. Among authors: lin sh. Front Biosci. 2007 May 1;12:3273-86. doi: 10.2741/2311. Front Biosci. 2007. PMID: 17485298 Review.

9

A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells.

Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. Chen N, et al. Among authors: lin sh. Cancer Res. 2007 Jul 15;67(14):6544-8. doi: 10.1158/0008-5472.CAN-07-1330. Cancer Res. 2007. PMID: 17638862 Free PMC article.

10

Current trials using bone-targeting agents in prostate cancer.

Tu SM, Lin SH. Tu SM, et al. Among authors: lin sh. Cancer J. 2008 Jan-Feb;14(1):35-9. doi: 10.1097/PPO.0b013e318161d32d. Cancer J. 2008. PMID: 18303481 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,738 results

Search Page

Filters